Activity of MSI-78, h-Lf1-11 and cecropin B antimicrobial peptides alone and in combination with voriconazole and amphotericin B against clinical isolates of Fusarium solani

J Mycol Med. 2021 Jun;31(2):101119. doi: 10.1016/j.mycmed.2021.101119. Epub 2021 Feb 3.

Abstract

Fusarium infections have been associated with high mortality rates due to the lack of definition of an ideal treatment strategy. Antimicrobial peptides (AMPs) have potential antifungal activity. Therefore, investigating the in vitro activity of these molecules alone and in association with conventional antifungals against clinical isolates of Fusarium was the aim of this study. Fusarium solani (n=10) strains were tested against the AMPs, MSI-78, h-Lf1-11 and cecropin B in accordance with CLSI protocol. Further, a checkerboard assay for its combination with amphotericin B or voriconazole, was carried out. MSI-78, h-Lf1-11 and cecropin B exhibited antifungal activity against F. solani strains tested with MICs ranging from 20 to 320mg/L. Satisfactory percentage of synergism was demonstrated for all evaluated combinations, ranging from 70 to 100%. The use of AMPs combined with amphotericin B and voriconazole antifungals has great synergistic potential and deserve to be evaluated in murine models of fusariosis.

Keywords: Antimicrobial peptides; Cecropin B; Fusarium solani; MSI-78; h-Lf1-11.

MeSH terms

  • Amphotericin B / pharmacology*
  • Antifungal Agents / pharmacology*
  • Drug Combinations
  • Drug Synergism
  • Fusarium / drug effects*
  • Humans
  • Microbial Sensitivity Tests
  • Pore Forming Cytotoxic Proteins / classification
  • Pore Forming Cytotoxic Proteins / pharmacology*
  • Voriconazole / pharmacology*

Substances

  • Antifungal Agents
  • Drug Combinations
  • Pore Forming Cytotoxic Proteins
  • Amphotericin B
  • Voriconazole

Supplementary concepts

  • Fusarium solani